Aditxt, Inc. (Nasdaq: ADTX), a social innovation platform focused on health innovations, has outlined its growth vision under the new bitXbio™ strategy. This framework is designed to integrate public markets, blockchain and Web3 technologies, and digital asset treasuries to accelerate breakthrough health innovations, aiming to transform Aditxt into a social innovation platform for a global community of stakeholders.
The strategic evolution includes a forthcoming Special Meeting of Stockholders. Aditxt has filed a Preliminary Proxy Statement with the U.
S. Securities and Exchange Commission, seeking shareholder approval for an Employee Stock Purchase Plan (ESPP) and a non-binding advisory vote on a proposed name change from “Aditxt, Inc.” to “bitXbio, Inc.” The company states the name change reflects its transition into a broader platform connecting public markets, blockchain, Web3, digital assets, and life sciences operating entities. The ESPP is intended to foster an ownership culture by enabling employees to purchase common stock through payroll deductions.
Central to the bitXbio™ ecosystem is the expansion of its global community. Currently composed of Aditxt shareholders, the company plans to evolve into a participatory life sciences platform where public equity and blockchain communities converge. This aims to decentralize involvement in advancing health innovations, promote transparent engagement, and align interests across all stakeholders.
A key layer of the bitXbio™ strategy is a planned Digital Asset Treasury (DAT), a blockchain-enabled financial architecture. This treasury is envisioned to capture potential value across Aditxt’s portfolio of innovative health companies. Subject to fund availability and market conditions, the DAT may include a crypto reserve of core cash equivalent digital assets, a native utility token to incentivize contributions and rewards within the bitXbio ecosystem, and tokenized representations of Aditxt’s ventures and partnerships. This hybrid treasury model is designed to reflect the value creation from Aditxt’s portfolio companies. Aditxt has clarified that as of the date of this announcement, it has not invested in or currently holds any digital assets.
Aditxt continues to apply its Acquire–Build–Commercialize (ABC) model to support its portfolio companies. Pearsanta, Aditxt’s precision diagnostics subsidiary, has announced a planned initial public offering (IPO) projected for 2026, contingent on market conditions. Pearsanta focuses on commercializing its Mitomic® and Adductomics testing platforms for early cancer and disease detection, currently completing clinical validation studies and expanding operations at its CLIA/CAP-certified laboratory in Richmond, Virginia.
In women’s health, Evofem, where Aditxt holds Series F-1 Convertible Preferred Stock with an aggregate stated value of $26,280,000 and convertible notes totaling $3,730,769, announced on October 20, 2025, its intention to regain a national exchange listing and pursue additional growth capital. Evofem markets two FDA-approved products: PHEXXI®, a hormone-free contraceptive gel, and SOLOSEC®, a single-dose treatment for bacterial vaginosis and trichomoniasis. Both Pearsanta’s proposed IPO and Evofem’s efforts to relist are considered significant steps toward Aditxt’s broader 2026 monetization and growth strategy.
Amro Albanna, Co-founder and Chief Executive Officer of Aditxt, commented, “Aditxt is building the foundation for long-term growth through innovation and participation. The bitXbio™ strategy is a structural evolution and we believe it will be the blueprint for transforming how health innovations are discovered, built, and commercialized on a global scale.”
Aditxt, Inc. operates as a social innovation platform accelerating health innovations through an ecosystem of research institutions, industry partners, and shareholders. Its mission is to “Make Promising Innovations Possible Together” across four programs focused on autoimmunity, cancer and early disease detection, infectious diseases, and women’s health. Pearsanta specializes in precision health diagnostics, utilizing its Mitomic® Technology Platform for non-invasive, blood-based liquid biopsy tests for early cancer detection.
